MBX Biosciences, Inc.
Company Stats
- Market Cap
- $2.8B
- as of Sep 30, 2026
- Shares Outstanding
- 48.2M
- Free Float
- 61.1%
Income Statement
- Operating Income
- -$98.1M
- Net Income
- -$87.0M
- EBITDA
- -$97.8M
Cash Flow
- Free Cash Flow
- -$81.9M
- FCF Yield
- -2.9%
- Owner FCF Yield
- -3.2%
Balance Sheet
- Cash & Equivalents
- $75.3M
Returns & Capital
- Share Repurchases
- $19,000
- SBC, 3Y Avg
- $5.3M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$81.9M | — |
| FY2024 | — | -$55.6M | — |
| FY2023 | — | -$32.1M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of November 4, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
GLP-1 companies reshape access and detail treatment dropouts
Stronger demand supports expansion as pricing diverges